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Background: Mutations in the Cu/Zn superoxide dismutase gene (SOD1) are responsible for 20% of familial forms
of amyotrophic lateral sclerosis (ALS), and mutant SOD1 has been shown to have increased surface hydrophobicity
in vitro. Mutant SOD1 may adopt a complex array of conformations with varying toxicity in vivo. We have used a
novel florescence-based proteomic assay using 4,4’-bis-1-anilinonaphthalene-8-sulfonate (bisANS) to assess the
surface hydrophobicity, and thereby distinguish between different conformations, of SOD1and other proteins in situ.
Results: Covalent bisANS labeling of spinal cord extracts revealed that alterations in surface hydrophobicity of
H46R/H48Q mutations in SOD1 provoke formation of high molecular weight SOD1 species with lowered solubility,
likely due to increased exposure of hydrophobic surfaces. BisANS was docked on the H46R/H48Q SOD1 structure at
the disordered copper binding and electrostatic loops of mutant SOD1, but not non-mutant WT SOD1. 16
non-SOD1 proteins were also identified that exhibited altered surface hydrophobicity in the H46R/H48Q mutant
mouse model of ALS, including proteins involved in energy metabolism, cytoskeleton, signaling, and protein quality
control. Heat shock proteins (HSPs) were also enriched in the detergent-insoluble fractions with SOD1. Given that
chaperones recognize proteins with exposed hydrophobic surfaces as substrates and the importance of protein
homeostasis in ALS, we crossed SOD1 H46R/H48Q mutant mice with mice over-expressing the heat shock factor 1
(HSF1) transcription factor. Here we showed that HSF1 over-expression in H46R/H48Q ALS mice enhanced
proteostasis as evidenced by increased expression of HSPs in motor neurons and astrocytes and increased solubility
of mutant SOD1. HSF1 over-expression significantly reduced body weight loss, delayed ALS disease onset, decreases
cases of early disease, and increased survival for the 25th percentile in an H46R/H48Q SOD1 background. HSF1
overexpression did not affect macroautophagy in the ALS background, but was associated with maintenance of
carboxyl terminus of Hsp70 interacting protein (CHIP) expression which declined in H46R/H48Q mice.
Conclusion: Our results uncover the potential importance of changes in protein surface hydrophobicity of SOD1
and other non-SOD1 proteins in ALS, and how strategies that activate HSF1 are valid therapies for ALS and other
age-associated proteinopathies.
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It has been proposed that exposure of hydrophobic
surfaces increases the propensity of non-native proteins
to oligomerize and form aggregates in a wide range of
age-associated neurodegenerative diseases including amyo-
trophic lateral sclerosis (ALS), Alzheimer’s (AD), Parkinson’s
(PD), and Huntington’s diseases. ALS is the most common
adult motor neuron disease characterized by progressive
degeneration of motor neurons, which results in muscle
atrophy and weakness, followed by paralysis and death. A
number of different mutations in genes encoding Cu/Zn
superoxide dismutase (SOD1) [1], TAR DNA binding pro-
tein 43 (TDP-43) [2], and 17 others are associated with fa-
milial forms of ALS (fALS), which make up 10% of total
ALS cases. The first known genetic link to fALS was
SOD1, which is responsible for 20% of familial cases, and
over 150 mutations in SOD1 have been described [3].
SOD1 mutations can be grouped into two families based
on their biophysical effects to the protein: pseudo-wild-
type mutants which retain metal binding and enzyme ac-
tivity, and metal binding region mutants such as H46R/
H48Q, which have only partial to no metal binding abil-
ity and reduced or no enzyme activity [4,5]. Despite be-
ing responsible for the disproportionation of superoxide
radicals to oxygen and hydrogen peroxide, mutations in
SOD1 are known to be toxic due to a gain of function
rather than a loss of function [6]. Increased surface
hydrophobicity of SOD1 mutants is a common feature
[7,8] and may be important in gain of functionality
through a structure-function relationship, however the
degree to which soluble mutant SOD1 is misfolded in situ
is unknown and difficult to measure using conventional
assays. Changes in protein surface hydrophobicity are
important because exposure of hydrophobic domains may
facilitate the formation of new protein-protein interactions
and aggregation of proteins which are observed in all
cases of ALS. If allowed to persist in vivo, surface
exposed hydrophobic domains could lead to forma-
tion of oligomers or seeding of amorphous or fibrillar
protein aggregates that correlate with cellular toxicity
[9,10]. Importantly, substrate specificity of major heat
shock proteins (HSPs) is dictated by sequence-specific
hydrophobic amino acids that frequently occur in
proteins but are usually buried and not surface-
exposed [11-14]. Thus, exposed surface hydrophobicity is
a significant recognition signal for HSP binding and
subsequent re-folding or degradation by chaperones
and co-chaperones via the ubiquitin proteasome sys-
tem (UPS) [15] or autophagy [16].
Soluble, conformationally altered proteins and those
with increased surface hydrophobicity are difficult to
measure and screen for in biological samples without
prior fractionation and purification, and available methods
are not amenable to locating the specific domains whereunfolding occurs. In addition, difficulties in replicating the
off-pathway folding events that occur in vivo [17] make
measuring conformationally altered species in situ advan-
tageous. To address these difficulties, we have previously
developed a novel fluorescence-based proteomic assay
using 4,4’-bis-1-anilinonaphthalene-8-sulfonate (bisANS)
that can detect changes in protein conformation on the
basis of changes in protein surface hydrophobicity from
soluble in situ tissue proteomes [18,19]. Using this assay
we have found that changes in protein conformation do
occur in skeletal muscle during ALS progression, experi-
mental denervation, and muscle injury [18,20,21], and that
the bisANS incorporation sites can be mapped onto pro-
teins [21] for further targeting studies with conformation-
specific antibodies [22], or other methods. In this study,
we measure changes in surface hydrophobicity of proteins
from the spinal cords of H46R/H48Q mice in order to
examine the in situ surface hydrophobicity of soluble
mutant SOD1 and non-SOD1 proteins from this model.
By covalently labeling proteins with the conformation-
sensitive dye bisANS, which fluoresces when it binds to
apolar surfaces, we have found that the H46R/H48Q
mutation in SOD1 provokes formation of high molecu-
lar weight SOD1 species with a lower solubility due to
increased exposure of hydrophobic surfaces. Further-
more, we have uncovered changes in the surface hydro-
phobicity profile of 16 non-SOD1 proteins that are
involved in energy metabolism pathways, cytoskeletal
framework/cell mobility, signaling, and protein quality
control systems.
Heat shock factor 1 (HSF1) is a 57 kDa member of
the HSF family, and is the major regulator of HSP ex-
pression [23]. Given that HSPs are cytoprotective and
recognize exposed surface hydrophobicity in their selec-
tion of substrates, HSF1 is an attractive pharmacological
target. Several pharmacological activators of HSF1 are
known, and function through inhibition of the prote-
asome or negative regulators of HSF1, such as HSP90.
The hydroxylamine compounds bimoclomol and arimo-
clomol prolong the activation of HSF1. Arimoclomol
was tested on the G93A mouse model of ALS and it was
found to increase lifespan by 22% [24] and is currently
in phase 2/3 clinical trials for ALS [25]. The arimoclo-
mol treated mice had elevated levels of HSP70 and 90
compared to untreated G93A mice, suggesting that HSP
expression through the HSF1 system was protective in
ALS, however it is unknown whether metal binding re-
gion mutants will be protected by enhancing protein
homeostasis. Riluzole, an FDA approved drug to treat
ALS has been shown to increase latent HSF1 levels and
enhance the heat shock response (HSR) [26,27]. Import-
antly, increasing levels of HSF1 by the use of transgenes
[28] or through glutamine and the CAAT enhancer-
binding protein-β (C/EBP-β) [29], are alternate ways to
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of the HSF1 inhibitor HSP90. This is especially important
for motor neurons, which are reported to have a high
threshold for activation of HSF1[30]. Several studies have
shown that the over-expression of HSF1 extends lifespan
and protects against various types of pathologies. For ex-
ample, in C. elegans over-expression of HSF1 extends life-
span [31], while its inhibition shortens lifespan. Activation
of HSF1 using the HSP90 inhibitor 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) led to an extension
in lifespan of a drosophila model of ALS, owing to the
upregulation of the drosophila ortholog of αB-crystallin
[32]. We and others have demonstrated a protective role
of HSF1 against protein misfolding and aggregation in
other neurodegenerative diseases, including AD [33],
Huntington’s disease [34], and prion diseases [35]. Taken
together, these studies confer the beneficial effects of an
HSF1-based ALS therapy and an important role of the
HSF1-mediated HSR in protecting against ALS.
We have created a transgenic mouse that over-expresses
human HSF1 (HSF1+/0) 2-4 fold in all tissues especially
the CNS [28]. We have shown that HSF1+/0 mice have
an enhanced HSR [28], and are protected from AD-like
deficits in memory [36]. In the current study, the effect
of HSF1 over-expression in a mouse model of ALS was
examined and found to significantly delay loss of body-
weight, disease onset, early disease, and survival in the
25th percentile suggesting that enhanced control of
protein surface hydrophobicity by upregulating HSF1
is a potential target for the treatment of ALS and other
proteinopathies.Results
Soluble Mutant SOD1 in spinal cord extracts has
increased surface hydrophobicity
In order to assess the global distribution of proteins
with altered exposure of surface hydrophobicity in the
spinal cords of symptomatic ALS mice, the soluble S1
fraction was labeled with bisANS and separated by 2D
gel electrophoresis (Figure 1A). As shown in Figure 1B
spots corresponding to human SOD1 were identified by
MALDI-TOF mass spectrometry (Table 1) and further
confirmed by Western blot using unlabeled spinal cord
extracts as specific for SOD1 (Additional file 1: Figure S1).
These spots specific for SOD1 were then quantitated for
their bisANS fluorescence and normalized for protein
by Sypro Ruby in order to determine their hydrophobi-
city ratio (Figure 1B and C). We observed that SOD1
separated into multiple spots with different isoelectric
points, as previously shown by others in unlabeled extracts
[37]. SOD1 spot numbers 153, 151, and 149 (Figure 1B&C)
showed significant increases in the hydrophobic ratio
compared to WT SOD1. Increased surface hydrophobicityof mutant SOD1 suggests that it may have increased
propensities for aggregation and/or toxicity [38].
Non-SOD1 proteins with altered surface hydrophobicity
in soluble fractions of spinal cord from H46R/H48Q mice
Since the toxic gain of function acquired by mutations
in SOD1 may also alter non-SOD1 proteins in the spinal
cord, we quantitated the non-SOD1 spots in the bisANS
labeled extracts separated by 2D gels shown in Figure 1.
We observed conformational alteration in a number of
non-SOD1 proteins, and their fold changes in protein
level and hydrophobicity ratio with respect to non-mutant
WT mice were examined (Table 1 and Figure 1).
We examined one of the non-SOD1 proteins ubiquitin
carboxyl hydrolase L1 (UCHL1) in more detail, due to
its role in maintaining mono-ubiquitin pools and abun-
dance in spinal cord. Changes in UCHL1 surface hydro-
phobicity were found to correlate with a dimeric state in
recombinant human UCHL1 separated by size exclusion
chromatography into monomeric and dimeric states
(Additional files 2: Figures S2 and Additional files 3:
Figure S3).
BisANS docked to multiple sites around the metal
binding region of H46R/H48Q SOD1
In order to investigate possible binding sites of bisANS
in WT or mutant SOD1, crystal structures of dimeric
WT holo human SOD1 [2C9V] and monomeric H46R/
H48Q apo SOD1 [3GQF] were docked with bisANS
(Figure 2), as WT holo SOD1 is known to exist as a
dimer, while H46R/H48Q has been reported to be poorly
metallated and can exist as a monomer [39,40]. As shown
in Figure 2, bisANS (colored blue) had one energetically
and geometrically favorable binding site between WT
SOD1 monomers, but H46R/H48Q had multiple possible
binding sites around the copper binding (colored green)
and electrostatic loops (colored red) of SOD1, which have
been reported to be disordered in H46R/H48Q SOD1[39].
These data were consistent with in situ data (Figure 1)
showing that H46R/H48Q had a greater degree of exposed
surface hydrophobicity than wild-type, likely due to in-
stability and greater exposure of the metal binding region
in SOD1.
SOD1 and chaperones enriched in detergent insoluble
fractions
In order to determine whether the solubility of mutant
SOD1 correlated with the observed differences in hydro-
phobicity, we examined spinal cord extracts for the
presence of SOD1 by differential detergent extraction
(Figure 3A). In the Coomassie stained soluble S1 frac-
tion, SOD1 migrates as a monomer under reducing and
denaturing SDS page at 17 kDa, and differences in levels
of SOD1 between WT TG and H46R/H48Q are affected
Figure 1 Altered surface hydrophobicity of mutant SOD1 and non-SOD1 proteins in the spinal cords of symptomatic ALS mice. A)
Representative 2D gels of wild type transgenic human SOD1 (WT TG, n = 8) and H46R/H48Q (n = 12) with molecular weights (left axis) and
isoelectric points (pI, upper axis). Spots that significantly differed from WT TG in hydrophobic ratio are circled and annotated based on the gene
names of their accession numbers identified by MALDI-TOF mass spectrometry. B) Enhanced region of 2D gels containing WT SOD1 and H46R/
H48Q mutant SOD1 proteins. BisANS fluorescence and corresponding total protein stained with Sypro Ruby are shown. Quantitated SOD1 spots
are shown with numbered ellipses and correspond to the quantitated hydrophobic ratio shown in C). Bars represent the mean hydrophobic ratio
+/- standard deviation of 10- 8 mice per group. *p<0.05, **p<0.01 by one-way ANOVA.
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SOD1 formed high molecular weight bands in the P2
and P3 fraction (Figure 3A, arrow), and showed high
molecular weight smearing corresponding to SOD1
(Figure 3A, vertical bar and asterisk), which was par-
tially resolved by reducing the sample with dTT. In
pellet 3, we also observed a dramatic increase in the
level of chaperones such as HSP70 and αB-crystallin,
suggesting that these chaperones were bound to mutant
SOD1 as has been shown with other SOD1 mutants[41]
(Figure 3B).
Effects of over-expression of HSF1 in H46R/H48QxHSF1
mice
Because chaperones and HSPs bind to exposed surface
hydrophobic domains to assist protein re-folding ordegradation, mutant H46R/H48Q SOD1 mice were crossed
with the HSF1+/0 transgenic mice (H46R/H48QxHSF1) in
order to determine the effects of HSF1 upregulation
on disease progression of ALS. H46R/H48QxHSF1 were
identified by PCR, and HSF1 over-expression was verified
by Western blot of spinal cord extracts (Figure 4A) in mice
at 222 days. HSF1 expression in the H46R/H48QxHSF1
symptomatic mice was three-fold higher (p = 0.0004) in the
spinal cord compared to H46R/H48Q and WT TG litter-
mates. Soluble levels of chaperones HSP70 (Figure 4B) but
not αB-crystallin (Figure 4C) were elevated in the spinal
cords of H46R/H48QxHSF1 mice, while levels of HSP70
and αB-crystallin were elevated in the P1 and P3 frac-
tions of the spinal cord, indicating a more robust HSR
in H46R/H48QxHSF1 mice. Differences in HSP70 and
αB-crystallin could be detected in total homogenates
Table 1 Protein identification table and hydrophobic ratios





















71 kDa protein (Hsc70)
P63017 44 15 108 2.3e-06 28 1.43 (0.06) 1.37* 0.0001
36 13 86 4.1e-04 25
85 19 96 3.4e-05 33
102 25 110 1.4e-06 37
Dihydropyrimidinase-
related protein 2 (Dpysl2)
O08553 27 9 70 1.5e-02 19 1.33 (0.16) 2.06* 0.0080
52 12 71 1.2e-02 24 1.24 (0.31) 2.19* 0.0256
Glial fibrillary acidic
protein isoform 1 (Gfap)
P03995 87 24 148 2.3e-10 46 0.95 (0.32) 1.91* 0.0119
Tubulin beta-4B chain
(Tubb4b)
P68372 45 13 97 2.6e-05 27 1.25 (0.33) 2.08* 0.0062
Alpha-enolase (Eno1) P17182 37 18 183 7.2e-14 42 0.99 (0.98) 3.08* 0.0118
Actin, cytoplasmic 2
(Actg1)
P63260 76 16 101 1.1e-05 45 1.62 (0.01) 0.84 0.0467
29 9 80 1.5e-03 30 1.63 (<.01) 0.72* 0.0020
Fructose-bisphosphate
aldolase C (Aldoc)
P05063 33 15 138 2.3e-09 45 1.13 (0.65) 1.13 0.0128
65 16 116 3.6e-07 46 0.96 (0.92) 2.98* 0.0189
L-lactate dehydrogenase B
chain (Ldhb)
P16125 35 9 76 3.5e-03 20 1.00 (0.99) 1.67* 0.0284
46 10 77 2.6e-03 28 1.11 (0.64) 1.21 0.7792
Phosphoglycerate mutase
1 (Pgam1)
Q9DBJ1 37 9 85 4.5e-04 46 1.64 (0.20) 2.07* 0.0136
29 11 125 4.6e-08 52 1.42 (0.16) 1.14 0.6404
14-3-3 zeta (Ywhaz) P63101 67 13 80 1.6e-03 35 3.25(<.01) 0.35*** 0.0006
14-3-3 protein gamma
(Ywhag)
P61982 55 12 78 2.3e-03 31 2.26 (<.01) 0.47*** 0.0001
Peroxiredoxin-6 (Prdx6) O08709 39 15 135 4.6e-09 53 1.48 (0.02) 0.75* 0.0442
Ubiquitin carboxy-terminal
hydrolase L1 (Uchl1)
Q9R0P9 40 10 75 4.2e-03 42 2.28 (0.02) 0.55* 0.0141
28 10 90 1.6e-04 42 2.11 (0.04) 0.57** 0.0006
Adenylate kinase
isoenzyme 1 (Ak1)
Q9R0Y5 15 6 73 7.6e-03 37 1.33 (0.48) 0.59* 0.0113
Phosphatidylethanolamine-
binding protein 1 (Pebp1)
P70296 15 6 82 8.1e-04 48 1.82 (0.04) 0.66* 0.0179
12 5 70 1.5e-02 36 1.36 (0.20) 0.85 0.6637
Peptidyl-prolyl cis-trans
isomerase A (Ppia)
P17742 56 18 113 7.2e-07 57 0.76 (0.37) 1.62 0.0356
48 14 91 1.1e-04 40 1.11 (0.76) 4.44** 0.0106
Human Cu, Zn Superoxide
Dismutase (SOD1)
P00441 40 8 76 7.0e-03 47 0.42 (<.01) 1.75* 0.0241
14 6 80 2.2e-03 28 0.52 (0.04) 1.13 0.0335
36 8 67 4.6e-02 34 0.45 (0.01) 2.08** 0.0051
28 7 74 9.2e-03 38 0.63 (0.13) 1.46* 0.0046
Protein IDs and gene names (in parentheses) are shown as well as fold-changes in their respective hydrophobic ratios and abundance with respect to matched
WT TG spots. Statistical significance is indicated by asterisks *p = 0.05, **p = 0.01, ***p < 0.01 for ANOVA tests and p values of student’s t test are reported
in parentheses.
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TG controls (Additional file 4: Figure S4). Disease progres-
sion can be followed by weight loss, and has been reported
as a reliable marker of healthspan, as well as symptom and
disease onsets in ALS mouse models. Hence, the body
weights for H46R/H48Q and H46R/H48QxHSF1 cohorts
were followed. H46R/H48QxHSF1mice (n=19) maintained
body weights significantly better overall when comparedto H46R/H48Q mouse littermates (n=20) (Figure 5A).
Disease onset, the period of time when mice reached their
maximum body weight, was also significantly delayed by
over-expression of HSF1 (p=0.0286, Figure 5B). Initiation
of early disease was calculated for H46R/H48QxHSF1 and
H46R/H48Q littermates using body weights as described
in the Methods. Compared to the H46R/H48Q littermates,




















































Figure 3 Mutant SOD1 and chaperones co-fractionate in the detergent insoluble fractions. Spinal cord extracts were subjected to
differential detergent extraction and A) the soluble fraction was electrophoresed under reducing and denaturing conditions and stained with
Coomassie (S1) and P1-P3 fractions were immunoblotted for SOD1 under non-reducing or reducing conditions (P1-P3). Asterisks indicate the
position of the monomeric SOD1. High molecular weight reactivity to the SOD1 antibody was detected in the H46R/H48Q extracts but not WT TG
(indicated by vertical bar). High molecular weight reactivity to SOD1 diminished with addition of a reducing agent, however a band
corresponding to dimeric SOD1 persisted and is indicated by an arrow. B) Inducible heat shock protein 70 and αB-crystallin co-fractionated
with mutant SOD1 in the detergent insoluble fractions of spinal cord. *p = 0.05, **p = 0.01, Bars represent the mean of 6 mice +/− SD.
WT holo dimeric SOD1 H46R/H48Q apo monomer 
-8.7
-7.1-6.0
Figure 2 BisANS docking with SOD1. BisANS (blue) docked with WT human SOD1 [2C9V] and H46R/H48Q [3GQP]. The zinc loop (aa49-84) is
colored green, and electrostatic loop (aa121-144) is colored red. Amino acids 46 and 48 are colored magenta, copper ions (orange), and zinc ions
(green). Binding energies are given for bisANS binding sites in kcal/mol. H46R/H48Q possess a binding site for bisANS in the metal binding
region, whereas holo WT dimeric SOD1 does not.
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Figure 4 Expression of HSF1 and distribution of HSPs in spinal cord. A) Western blot of HSF1 in spinal cord homogenates from normal and
symptomatic control mice normalized with HSC70, demonstrating the over-expression of HSF1 in H46R/H48QxHSF1 mice compared to H46R/
H48Q littermates. B) Spinal cords were extracted with detergents of increasing ionic strength as described in the methods. S1 and P1-3 extracts
were immunoblotted for inducible HSP70 (B) or αB-crystallin (C). Asterisks are given at the position of the expected monomeric protein. p is indi-





Figure 5 Effect of HSF1 over-expression on body weight loss and healthspan of H46R/H48Q mice. H46R/H48Q mice (Solid line) n = 20
and H46R/H48QxHSF1 (dashed line) n = 19. A) Beginning at 3 weeks of age, weekly averages of body weight are plotted for the
survival cohort for WT (green circles), HSF1 (blue squares), H46R/H48Q (red triangles), and H46R/H48QxHSF1 (gold triangles). Asterisks
indicate significant differences in H46R/H48QxHSF1 vs. H46R/H48Q at the *p<0.05, **p<0.01, and ***p<0.001 level. B) Disease onset
was determined as the time animals reached their maximum bodyweight. C) Early disease was defined as a drop of 10% of the
mouse maximal weight. D) Survival was defined as the point at which animals could not right themselves within 30s after being
placed on their side.
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(p=0.0317) compared to H46R/H48Q (Figure 5C). While
overall survival was unaffected (Figure 5D), survival of
the 25th percentile was significantly different (p=0.017).
Ubiquitous over-expression of HSF1 protected H46R/H48Q
against ALS as evidenced by their improved body weight
retention and delayed disease onset, symptom onset, and
early survival. Also, over-expression of HSF1 led to a non-
significant increase (p=0.064) in soluble mutant SOD1 and
significantly reduced its levels in detergent insoluble fractions
by 34% (p=0.027) (Figure 6). These data suggest that
overexpression of HSF1 may have altered the solubility of
SOD1 and improved protein homeostasis in motor
neurons. To examine this, spinal cords were sectioned
and the lumbar region was examined (Figure 7). As shown,










Figure 6 Effect of HSF1 over-expression on mutant SOD1
solubility. SOD1 in the soluble S1 and detergent soluble fractions
P1-P3. Asterisks are given at the position of the expected monomeric
SOD1. Bars represent an n = 6 +/− SD.by overexpression of HSF1, as choline acetyltransferase
(ChAT) positive motor neurons contained fewer SOD1
puncta and exhibited a more uniform staining for
SOD1 in cell bodies compared to H46R/H48Q. This
corresponded to a more intense staining for HSP70 in
ChAT positive motor neurons compared to H46R/H48Q
tissues. Likewise, αB-crystallin staining showed a
striking change in its distribution in the H46R/H48Q
tissues going from a diffuse pattern as seen in WT
TG tissues to a more punctate nuclear pattern as
seen in the large SOD1 positive cell bodies in the
H46R/H48Q spinal cord (Figure 8). Overexpression
of HSF1 appeared to restore this shift to resemble
the appearance of WT TG. In addition to motor
neurons, GFAP positive astrocytes also contributed a
major portion of the HSP70 and αB-crystallin staining
(Additional file 5: Figure S5).
One possible explanation for the restoration of SOD1
solubility in tissues of H46R/H48QxHSF1 mice could be
explained by enhanced chaperone-mediated turnover of
mutant SOD1. Mutant SOD1 has been shown to be de-
graded by both the proteasome and macroautophagy
[42]. Since HSF1 could affect induction of macroauto-
phagy, we next examined levels of membrane-bound
microtubule-associated proteins 1A/1B light chain 3A
(LC3-II). Levels of LC3-II protein remained elevated in
H46R/H48QxHSF1 mice as observed in H46R/H48Q
(Figure 9A), while normalized levels of p62 were also
unchanged by HSF1 overexpression (Additional file 3:
Figure S3B) indicating that rates of macroautophagy were
not affected. The carboxyl terminus of Hsp70 interacting
protein (CHIP) is an important co-chaperone that has
been shown to play a role in the polyubiquitination
and proteasomal degradation of mutant SOD1 when
bound to Hsp/Hsc70 [43]. To determine whether HSF1
over-expression would enhance CHIP expression, the
expression levels of CHIP in the spinal cords from
H46R/H48QxHSF1 mice were examined by Western blot.
Levels of CHIP were significantly decreased (p=0.001)
following mutant SOD1 over-expression, likely due to
a shift in protein turnover in ALS away from the
UPS, which was prevented by over-expression of HSF1
(Figure 9B).
Discussion
A change in protein surface hydrophobicity can be an
important indicator to determine alterations in protein
structure, and thus indicative of losses or toxic gain of
protein function. Exposure of protein surface hydrophobi-
city and disordered regions in proteins have been reported
to precede aggregation [38], and to be an important intrin-
sic quality of proteins that can determine whether they are
aggregation prone or capable of forming amyloid using
bioinformatic approaches [10]. In addition to intrinsic
Figure 7 Anterior horn region of lumbar spinal cord sections from mice at 220 days. Motor neuron choline acetyltransferase (ChAT)
positive cells (A-C, arrows) co-localized with SOD1 positive staining (D-F, arrows). H46R/H48Q mice exhibited small intracellular peri-nuclear
SOD1 reactive punctae (E, arrows), while H46R/H48QxHSF1 tissues had a more even intracellular distribution of SOD1 staining (F). This corresponded
with differences in HSP70 distribution to SOD1 reactive punctae in H46R/H48Q mice (H) while in contrast, co-localization with ChAT reactive cells in
H46R/H48QxHSF1 mice was stronger (I). Scale bar represents 10 μm.
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their surface through post-translational modifications,
mutations, or oxidative damage, which may not be pre-
dicted with bioinformatic approaches alone. SOD1 con-
tains a greek key β-barrel which can be exposed or unfold
due to SOD1 mutations near the metal binding region,
and conformation-specific antibodies targeting this site
can detect SOD1 in neuronal tissues of human familial
and sporadic ALS patients [44,45]. The bisANS related
compound ANS has similar properties to bisANS and has
been used to show that the point in time at which amyloi-
dogenic proteins exhibit their greatest toxicity correlates
with a surge in surface hydrophobicity [46]. Increased sur-
face hydrophobicity of the SOD1 mutant studied here in
situ and by others has been described using different
in vitro techniques [7,8,17,47]. In this proteomic study, we
have utilized a covalent photolabeling approach with the
hydrophobic dye bisANS to monitor the surface hydro-
phobicity of mutant SOD1 and other non-SOD1 proteins
in the spinal cord of H46R/H48Q mice.Consistent with several studies looking at the hydro-
phobicity of G93A or single mutant H46R or H48Q
SOD1 using similar hydrophobic dyes in vitro [38,46],
we observed alterations and an overall increase in
soluble SOD1 surface hydrophobicity of previously re-
ported isoelectric species of SOD1 [37] in the H46R/
H48Q double mutant of SOD1 in situ. Our in situ
analysis of the conformationally altered proteome shows
for the first time only a fraction of the total SOD1 sol-
uble pool exhibits these properties, and that the degree
of exposed surface hydrophobicity is varied among iso-
electric species of SOD1. These differences in surface
hydrophobicity are important, and could reflect differ-
ent conformational states that each mutant undergoes
in vivo during symptomatic stages of ALS, metallation
status of the protein [5], or may identify species of
SOD1 that are most toxic. We found that the metal
binding region appeared to be the most plausible target
of bisANS in mutant SOD1 (Figure 3), and this can be
confirmed by identification of the specific bisANS
Figure 8 Anterior horn region of lumbar spinal cord sections from mice at 220 days. SOD1 staining (A-C) and small SOD1 positive
punctae in H46R/H48Q vs. H46R/H48QxHSF1 tissues (C, arrows) co-localized diffusely with αB-crystallin throughout WT TG and H46R/H48QxHSF1
tissues (D,F). Strikingly, αB-crystallin staining appeared more punctate and localized to cell nuclei of SOD1 expressing cells (E,H, arrows and G-I)
in H46R/H48Q tissues. Scale bar represents 10μm.
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in future studies.
The surface hydrophobicity detected by bisANS cor-
related with the insolubility of mutant SOD1 and the
presence of high molecular weight species of SOD1 in




Figure 9 Effects of HSF1 over-expression on measures of protein qua
and immunoblotted for A) LC3-II or B) CHIP and normalized with Hsc70. Bupon disulfide bonds or mixed disulfides. While the
species of mutant SOD1 detected here with bisANS
were soluble species, the conformational alterations in
SOD1 alluded to by changes in surface hydrophobicity
may be indicative of toxic gain of function. Interestingly,
increases in surface hydrophobicity of WT SOD1 as.
HSC70
CHIP
lity control in ALS. Whole spinal cords were homogenized in 2%SDS
ars represent an n = 6 +/− SD.
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to bind, cleave DNA or RNA, and induce its aggregation
[47,48]. Mutant SOD1 has also been shown to display
increased binding to neurofilament (NFL) mRNA [49],
and to alter RNA homeostasis by binding to Hu antigen
R and T-cell internal antigen 1 (TIA1) related protein
[50], two key players in modulating stress granule forma-
tion and mRNA stability along with TDP-43. However it is
unknown whether the increased hydrophobicity associated
with the SOD1 mutants studied here enhances these
reported gains of function in SOD1. Further studies
are required to elucidate the direct impact that increased
protein surface hydrophobicity has on toxic gains of func-
tion in SOD1. Aggregates in spinal cords of ALS patients
as well as in the mice used in this study have been re-
ported to contain various chaperones such as HSP70
and αB-crystallin [41], intermediate filament proteins,
and others [51], supporting the idea that interventions
that enhance proteostasis might be beneficial in ALS.
Since SOD1 mutations and aggregation are only ob-
served in some ALS cases, there is good reason to suspect
that the toxic effects of mutant SOD1 may be indirect and
involve non-SOD1 proteins. For this reason, we also ex-
amined the changes in surface hydrophobicity of soluble
non-SOD1 proteins in the spinal cords from symptomatic
ALS mice. We found sixteen non-SOD1 proteins with sig-
nificantly altered surface hydrophobicity, and these could
be separated into groups such as energy metabolism, cyto-
skeletal organization, protein quality control, and signaling
based upon their reported functions.
Although too numerous to discuss all, a few of the
proteins in Table 1 deserve some discussion. Several
glycolytic proteins are “moonlighting proteins” and per-
form functions outside of glycolysis with implications for
neurodegenerative disease [21,52]. Changes in surface
hydrophobicity in glycolytic enzymes correlate well with
clinical and experimental observations that defects in
energy homeostasis are a common feature in subsets of
ALS patients [21,53,54]. In our study, we detected alter-
ations in surface hydrophobicity of several glycolytic en-
zymes and proteins important in energy homeostasis
including alpha-enolase, fructose-bisphosphate aldolase C,
L-lactate dehydrogenase B chain, phosphoglycerate mu-
tase 1, and adenylate kinase 1.
Alexander disease is a neurodegenerative disease caused
by mutations in the glial fibrillary acidic protein (GFAP),
leading to aggregates of GFAP and chaperones called
Rosenthal fibers [55]. We detected significant increases in
the surface hydrophobicity of GFAP, but whether the
changes in GFAP hydrophobicity observed in this study
were indicative of aggregation in ALS is unknown.
Defects in protein homeostasis and quality control are
hypothesized as important mechanisms in neurodegen-
erative diseases [56]. The constitutive chaperone Hsc70,which is involved in several aspects of protein homeosta-
sis, has been shown to bind to mutant SOD1 via inter-
action with CHIP to promote mutant SOD1 degradation,
and is found in spinal cord aggregates from both mice
[41] and humans [51]. In this study, surface hydrophobi-
city of Hsc70 in H46R/H48Q was significantly increased
compared to WT transgenic littermates. This is consistent
with the finding that increases in ANS binding are asso-
ciated with thermal denaturation of Hsc70 [57]. An-
other chaperone, peptidyl-prolyl cis trans isomerase A
(PPIA) also known as cyclophilin A, is an immunophilin
that binds cyclosporine A and catalyzes the conversion
of peptidyl-prolyl bonds from cis to trans. Over-expression
of cyclophilin A has been found to protect cells from
mutant SOD1-induced cell death [58], and to aggregate
with Hsc70 and 14-3-3 gamma in G93A mice [51]. It is
plausible that the alterations we observed in surface
hydrophobicity correlate with these activities of cyclo-
philin A, although it has not been directly tested.
UCHL1 is an abundant protein in motor neurons, and
deletions in the 7th and 8th exons cause gracile axonal
dystrophy in mice, characterized by motor/behavior ab-
normalities and shortened lifespan [59]. UCHL1 is a
monoubiquitin binding protein with weak ubiquitin
hydrolase activity that may function in maintaining
monoubiquitin pools [60]. UCHL1 has been shown to
form dimers that enhance a ubiquitin-ubiquitin ligase
activity [61]. In the same study this activity was associ-
ated with increased aggregation of α-synuclein in a cell
model system of PD. Thus, it would appear that
dimerization of UCHL1 promotes a gain of function ac-
tivity that is detrimental under certain circumstances.
In our study, we observed a decrease in surface hydro-
phobicity of UCHL1 (Figure 1, Table 1) that correlated
with a similar decrease in surface hydrophobicity of
UCHL1 between monomeric and dimeric forms in vitro
(Additional file 2: Figure S2A and B). These data suggest
that in ALS dimerization of UCHL1 is favored. Whether
decreased surface hydrophobicity of UCHL1 translates
into increased ubiquitin-ubiquitin ligation, or local deple-
tion of the monoubiquitin pool remains to be determined.
The surface hydrophobicity of the signaling proteins
14-3-3 gamma and zeta isoforms were found to be sig-
nificantly decreased. Originally highlighted in the brain
for their roles in activating tryptophan and tyrosine hy-
droxylases, 14-3-3 proteins were later proven to have
diverse functions mostly as scaffolding proteins, and
have been implicated in a variety of neurodegenerative
diseases [62]. With regards to ALS, 14-3-3 proteins have
been shown to modulate NFL mRNA stability [63] and
assist in targeting misfolded proteins to aggresomes by
linking Bcl-associated athanogene 3 (BAG3) to histone
deacetylase 6 (HDAC6) [64,65]. A triple phospho-mimetic
mutant S58E/S184E/T232E has been linked to decreased
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Phosphorylation of Serine 58 in 14-3-3 zeta has been char-
acterized as a molecular switch for induction of apoptotic
cell death [67]. Therefore, in addition to its solubility being
affected in ALS mice [51], changes observed in surface
hydrophobicity of 14-3-3 in this study may be indicative of
its phosphorylation.
Misfolded proteins are associated with exposed surface
hydrophobicity, and the proteins that we identified with
altered hydrophobicity likely represent metastable pro-
teins that are easily misfolded during proteotoxic stress.
Strikingly, Xu et al recently examined proteins that be-
came insoluble in the brains of mice expressing mutant
forms of amyloid precursor protein[68]. Many of the
same proteins that we found misfolded here in the spinal
cord of ALS mice were also found to be insoluble in the
brains of mice modeling AD, supporting a connection to
the misfolding we have measured using bisANS and the
downstream aggregation process that occurs during
proteotoxic stress. Misfolded proteins and proteins with
exposed hydrophobicity are recognized by chaperones
on the basis of surface hydrophobicity. Since we ob-
served increases in surface hydrophobicity of mutant
SOD1 and 16 other non-SOD1 proteins in the spinal
cord of H46R/H48Q mice, we set out to determine
whether over-expression of HSF1 would be protective
against SOD1 mutant-mediated ALS and alteration in
proteome surface hydrophobicity. As expected, over-
expression of HSF1 was detected in the spinal cord of
H46R/H48QxHSF1 mice by Western blot, and led to an
increase in the solubility of SOD1. HSF1 over-expression
led to a robust induction of HSP70 and αB-crystallin as
detected in some soluble and insoluble fractions which
could be detected as early as 197 days. However, HSP
induction was not able to completely reverse SOD1 aggre-
gation. Co-localization of HSPs by immunofluorescence
and increased co-fractionation of HSP70 and αB-crystallin
with SOD1 in insoluble fractions measured here, and the
observations that these HSPs bound to mutant SOD1
in vivo by others [41] suggests they were associated with
aggregated SOD1. Immunofluorescence of H46R/H48Q
mice also detected an increased number of cells with
nuclear localized αB-crystallin staining and speckles
that were absent in double transgenic mice (Figure 8E, H).
Recently nuclear localization of αB-crystallin has been
shown to be associated with stress and associates with the
survival of motor neuron complex[69]. Association of αB-
crystallin with alpha 7 subunits of the 20S proteasome
suggest it could also be involved in facilitating turnover of
bound aggregates [70]. This is supported by the observa-
tions that differences in protein homeostatic machinery
were detected in the UPS associated co-chaperone CHIP,
but not macroautophagy of H46R/H48QxHSF1 mice. ALS
is a multifactorial disorder affecting multiple cell typesand physiological phenotypes, and these are reflected in
transgenic mouse models of ALS[71]. H46R/H48QxHSF1
maintained a 3-fold increase in HSF1 expression through-
out the study, which led to retention in body weight
and delay in disease onset, early disease, and survival of
the 25th percentile with exception of overall survival of
the experimental cohorts (Figure 5). Motor neuron
death is an early event in the disease process, and is
responsible for the timing and early symptoms in ALS
[72], while astrocytes[73] and microglia [74] are re-
sponsible for disease progression suggesting that HSF1
over-expression had a primarily beneficial effect on
motor neurons, but not on astrocytes or microglia.
Conclusions
We show that changes in surface hydrophobicity as de-
tected by bisANS relate to important gains or losses of
function in soluble SOD1 and the non-SOD1 proteins
we identified. Importantly, this study demonstrates
that soluble fractions of mutant SOD1 are indeed mis-
folded and exhibit increased surface hydrophobicity,
which correlates with the insolubility of mutant SOD1
and may be indicative of toxic gain of function. In
future studies, mapping the bisANS incorporation sites
to the isoelectric species of mutant SOD1 and the
other non-SOD1 proteins that were altered will enable
these domains to be targeted in order to determine
their possible roles in ALS. Furthermore, the bisANS
fluorescent-based assay used here can be applied as
part of a high-throughput screening approach to iden-
tify compounds/drugs that interfere with the exposure
of hydrophobic surfaces of metastable proteins or pre-
vent aggregation. Over-expression of HSF1 was associ-
ated with maintenance in bodyweight, delayed disease
onset, progression, and early survivorship. These data
indicate that there is a functional and survival benefit
to over-expression of HSF1 and enhancing the heat shock
response, and validates therapeutic strategies aimed at
activating HSF1 for ALS models. This is the first study to
demonstrate that over-expression of full-length HSF1 is
beneficial in ALS, and further shows that increasing HSF1
protein may be an additional strategy to activate HSF1 ra-




Mice were housed in a temperature and humidity-
controlled vivarium at the Audie L. Murphy VA Hospital.
Wild type transgenic human SOD1 (WT TG) mice
were backcrossed to C57B6/J mice 4 times. The SOD1
H46R/H48Q mutant mice (H46R/H48Q) were gener-
ated by David Borchelt (line 139) [75] on a C3HeJ B6
background and backcrossed over 10 generations to a
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derived and maintained on a C57BL/6 background,
and the generation of these mice has been described
previously [28]. Male H46R/H48Q breeders were
mated with female HSF1+/0 mice to generate mice for
the survival cohorts, and the lifespans of the male
breeders were monitored to ensure they did not devi-
ate from parental lines due to mutant SOD1 copy loss.
Offspring were genotyped to obtain double transgenic
mice that contained both mutant H46R/H48Q and the
HSF1 transgene (H46R/H48QxHSF1). Genotyping was
performed by PCR using primers specific for the human
SOD1 gene [1] and as previously described for the human
HSF1 transgene [28]. Body weight measurements began
when mice reached the age of 120 days and recording was
performed bi-weekly until death (n=19/genotype). Disease
onset was calculated as the day a mouse reached its max-
imal bodyweight, while early disease is defined as the day
at which a 10% decrease in its maximal bodyweight was
observed, and survival is determined at the day at which a
mouse is unable to right itself when place on its side for
30s [76,77]. All procedures for handling animals in this
study were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) of the Audie
L. Murphy Memorial Veterans Hospital.
BisANS assay
Covalent UV photolabeling of bisANS to proteins was
performed essentially as described [21]. Briefly, soluble
fractions (S1) of spinal cord tissue were isolated on ice
by homogenization of tissue with 5 volumes of bisANS
labeling buffer (50 mM Tris 10 mM MgSO4 pH 7.4 plus
protease inhibitors) followed by centrifugation at 100,000g
for 1hr at 4°C. It has been shown that incubation of pro-
teins with high dye:protein ratios of 100:1 or more can
induce conformational changes in some proteins [78].
Therefore in all comparisons, we labeled 1 mg/ml solu-
tions of cytosolic protein with 200 μM bisANS with a
handheld 365 nm UV lamp (UVP, Upland, CA) for 30
minutes on ice in a 96-well plate with non-mutant
SOD1 over-expressing mice as controls. At this protein
concentration it was estimated that the dye:protein ratio
was approximately 8:1 based on abundance and molecu-
lar weights of Sypro Ruby spots in 2D gel profiles.
BisANS labeled proteins were then precipitated 1:1 with
20% trichloroacetic acid. Precipitates were centrifuged
at 4°C at 18,000g for 30 min, and pellets were washed
twice by disrupting with ice cold 1:1 ethanol:ethyl acet-
ate. Cleaned pellets were dried and then dissolved in
6M urea, 4% CHAPS, 0.4% ampholytes. For SDS PAGE
gels, 15 μg of protein was diluted in 6X laemmli buffer
and separated on 15% polyacrylamide gels. Following
electrophoresis, gels were imaged for bisANS and
stained with Sypro Ruby.2D gel electrophoresis
Following determination of protein concentration by BCA
assay, 4 μl of destreak reagent (GE Health) was added
to 200 μg of bisANS labeled protein, which was fo-
cused on 4-7 immobilized pH gradient (IPG) strips for
12 hr. Focused IPG strips were then washed in equili-
bration buffer (50 mM Tris buffer pH 8.8, 6M urea,
30% glycerol, 2% SDS) containing 10 mg/ml dithiothreitol
(dTT) for 15 min followed by 25 mg/ml iodoacetamide.
Equilibrated strips were then separated on 15% polyacryl-
amide gels, placed in 10% methanol at 4°C, and visualized
for bisANS fluorescence on a UV imager with a 365 nm
illumination source for 30 seconds (AlphaImager). 2D gels
were placed in fixing solution (10% methanol 7% acetic
acid) for 1hr and then stained in Sypro Ruby overnight
with gentle agitation. Following destaining with fixing
solution, gels were placed in doubly deionized water for
1 hr and then imaged for Sypro Ruby fluorescence on a
Typhoon 9410 imager (GE Health). BisANS and corre-
sponding Sypro Ruby spots were matched and quanti-
tated by densitometry using Imagequant (Molecular
Dynamics). Hydrophobic ratios were determined by div-
iding the bisANS densitometric value by corresponding
Sypro Ruby densitometric values. The mean hydropho-
bic ratios for each group were then compared using
one-way ANOVA. Spots with significantly different
hydrophobic ratios were picked using an ExQuest spot
cutter (Biorad).
Mass spectrometry
Picked spots were digested in gel with sequencing grade
trypsin (promega) overnight at 37°C. Peptide digests were
then spotted to a target with α-cyano-4-hydroxycinnamic
acid, and identified by matrix-assisted laser desorption
ionization time of flight (MALDI-TOF) mass spectrometry
(Voyager STR, Applied Biosystems). Peak lists were gener-
ated by Data Explorer version 4.0.0.0 (Applied Biosystems)
using advanced baseline correction peak width parameters
of 32, flexibility of 0.5, and degree of 0.1; noise filter
parameter of 0.7; gaussian smooth parameter of 5; noise
reduction parameter of 2.00. Trypsin autocatalytic
peaks were used to internally calibrate spectra, and were
excluded from peak lists for Mascot database searches.
Peptide mass fingerprints were then searched using
Mascot (Matrix Science) and the NCBInr 10/01/2012
database allowing 1missed cleavage site. Variable modi-
fications of carbamidomethylated cysteine and oxida-
tion of methionine were included and a peptide mass
tolerance of 100 ppm was used.
Western blotting
Insoluble material remaining from homogenized spinal
cords was sequentially extracted with detergents of
increasing ionic strength as described previously [21].
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100,000g the pellet was sonicated in bisANS labeling
buffer to remove cytosolic proteins and re-pelleted at
100,000g for 30 min. Next, pellets were extracted in the
same buffer containing 0.5% Nonidet P40 by sonication
and re-pelleted at 100,000g for 30 min. This supernatant
was termed P1. The remaining pellet was then sonicated
in P1 buffer containing 0.25%SDS and 0.5% deoxycholate
to isolate the P2 fraction, then P1 buffer containing 2%
SDS and 0.5% deoxycholate to isolate the P3 fraction. Pro-
tein extracts were then boiled in non-reducing or reducing
Laemmli buffer where indicated, and separated by 15%
SDS PAGE followed by a 2hr wet transfer at 100V to poly-
vinylidine fluoride membranes (Biorad). Membranes
were blocked in 5% milk Tris-buffered saline containing
tween 20 (TBST) containing 20mM Tris, 137mM NaCl,
and 0.4% tween 20 for 30 min at room temperature.
Membranes were incubated with sheep anti-human
SOD1 (1:1000, Calbiochem), mouse anti-UCHL1 (1:5,000
Abnova#H00007345-M01), mouse anti-Hsp70 (1:10,000,
Stressgen; SPA-810), rabbit anti-HSF1 (1:10,000 dilution,
Stressgen;SPA-901), heat shock cognate 70 (Hsc70)
(1:20,000 dilution, Stressgen SPA-815), rabbit anti-LC3
(1:2,500 dilution, Cell Signaling#2775), rabbit anti-CHIP
(1:1000, Cell Signaling#2080), rabbit anti-αB-crystallin
(1:2000, Abcam #ab13497), overnight at 4°C with gentle
agitation.
BisANS docking
BisANS was docked to SOD1 (dimeric WT metallated:
[2C9V] or monomeric apo H46R/H48Q:[3GQF]) using
Autodock Vina [79]. Docked pdb files were generated
and rendered by RasMol version 2.7.5.2.
Immunofluorescence Microscopy
Mice were perfused transcardially with PBS and spinal
cords were excised and fixed in PBS containing 4%
paraformaldehyde at 4°C until processing. Lumbar re-
gions of the spinal cord were imbedded in optimal cut-
ting temperature compound and sectioned at 30 μm
and affixed to poly-D-lysine coated slides. Sections were
blocked in 4% goat serum in TBST and stained with
choline acetyltransferase (1:250), glial fibrillary acidic
protein (1:500), SOD1 (1:500) Heat shock protein 70
(1:500), or αB-crystallin (1:500) overnight at 4°C in 1%
goat serum in TBST. Primary antibodies were visualized
with secondaries conjugated with Alexa 350, 488, or 594
at 1:250 in 1% goat serum in TBST. Slides were imaged
with an Olympus IX51 fluorescence microscope.
Statistical analysis
2D gel data were analyzed for significance using one-way
ANOVA. Post hoc tests were performed using Tukey’s test
at a significance value of 0.05. For those spots withsignificantly different hydrophobic ratios compared to WT
TG, the mean Sypro Ruby intensity and Western blot
densitometric analyses were compared between WT TG
and H46R/H48Q using a student’s t test. Disease onset,
early disease, and survival curves were compared using
the log-rank test (Wilcoxon).
Additional files
Additional file 1: Figure S1. Western blot for SOD1 on 2D separated
spinal cord. Spinal cords from WT TG mice were homogenized and
unlabeled proteins were separated by 2D gel electrophoresis according
to Methods. 2D gels were then equilibrated and blotted for human
SOD1. SOD1 immunoreactive spots were matched with 2D gel spots
for SOD1.
Additional file 2: Figure S2. Surface hydrophobicity of monomeric and
dimeric UCHL1. A) Recombinant monomeric (M) and dimeric (D) UCHL1
were fractionated by size exclusion chromatography and labeled with
5-molar excess bisANS and resolved by 12% SDS page, with unlabeled
UCHL1 as a control. B) The resultant bisANS fluorescence in monomeric
and dimeric preparations of UCHL1 were quantitated and normalized by
Sypro Ruby staining. *p<0.05 by Student’s t test.
Additional file 3: Figure S3. Recombinant UCHL1 UCHL1 protein was
prepared essentially as described [80] with the following modifications:
the induced cell pellet was resuspended in 4 mL PBS buffer/L culture
prior to chromatography. Cells were disrupted by passage twice through
a French pressure cell (Thermo Fisher) at 12,000 psi. Two peaks
containing UCHL1 eluted from the final S200 chromatography step; the
earlier peak was shown to correspond to the dimer by analytical gel
filtration and native PAGE, whereas the latter peak was consistent with
the monomer.
Additional file 4: Figure S4. Effect of HSF1 overexpression on
Chaperone and p62 levels in H46R/H48Q mice. Whole spinal cords were
homogenized in 2%SDS and immunoblotted for the A) HSP70 and
αB-crystallin or B) p62 and normalized with Hsc70. Bars represent an
n=6 +/- SD.
Additional file 5: Figure S5. Double immunofluorescence labeling of
anterior horn lumbar spinal cord. H46R/H48QxHSF1 tissues were stained
with HSP70 (red) and astrocyte marker Glial Fibrillary Acidic Protein
(GFAP, blue). Some of the tissue staining for HSP70 and
αB-crystallin can be accounted for by astrocytes as shown by colocalization
with GFAP. Scale bar represents 10 μm.
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